Full-Time

Commercial Training Director

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$188k - $282k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA + 1 more

More locations: London, UK

Hybrid role; work remotely up to two days per week.

Category
Training
Requirements
  • Experience in adult education principles including competency modeling
  • A proven track record of driving results through strong partnership with other functions and geographies
  • A track record of inspiring individuals to become open to change, designing and providing effective tools as needed to lead the individuals through the change process
  • Extensive experience within the commercial function, the pharmaceutical marketing function and marketing
  • Proven project management, presentation, interpersonal as well as verbal and written communication skills
  • Demonstrated ability to work independently and manage projects that require collaboration across functional areas including Marketing, Market Access, Commercial Operations, HR, Legal, Corporate Compliance, etc.
  • Solid coaching and mentoring skills that are constructive and motivational
  • Able to communicate effectively at all levels and present complex and/or new ideas with clarity and simplicity
  • Bachelor’s degree in related field required (i.e. Marketing, Business, Strategy, or equivalent)
  • This position requires experience in combination of Pharmaceutical Marketing, Life Science Consulting (Training Design & Development), or Pharmaceutical the equivalent combination of education and experience
Responsibilities
  • Reviews all marketing training programs to ensure they are aligned to the global marketing competency model
  • Responsible for global marketing training delivery and management
  • Review and refine the marketing competency model so that it is aligned to the priorities and vision of the commercial organization
  • Collaborates with HR Learning and Development business partners to ensure the competency model is included in all relevant HR tools and systems
  • Work with senior leadership and marketing leaders across the organization to design, develop and deliver marketing training that has been developed as part of a comprehensive curriculum to advance the marketing and commercial capabilities of the organization
  • Oversee and portfolio of marketing skills/capabilities training programs that are aligned to business priorities
  • Design and develop a plan to track and measure the impact of marketing training programs (both qualitative and quantitative measures)
  • Capable of delivering training modules and facilitating marketing training programs as appropriate
  • Owns the design and development of certain eModule developments and instructor led training courses
  • Oversee and curate the online Commercial Resource Library; collaborate with Corporate HR Learning & Development colleagues
  • Delivers foundational marketing training aligned to different levels (i.e. Brand Managers, Directors, etc.) that focuses on aligning teams on Vertex’s marketing philosophy and frameworks
  • Oversees and executes advanced marketing training events such as the Wharton Portfolio Leadership program aimed at high potential senior marketing and commercial leaders
  • Proactively identifies marketing trends and innovations (within Pharma and outside Pharma) to leverage within the marketing training program
Desired Qualifications
  • MBA or MS Marketing preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.